8 results
To determine whether fibrinogen concentrate infusion reduces perioperative blood loss and transfusion in patient experiencing clinically relevant microvascular bleeding during elective complex cardiac surgery and to determine whether its use is safe…
1. Clinically relevant reduction of symptom severity by use of Citrus/Cydonia comp. subcutaneous injections2. To examine the safety of treatment3. To examine treatment effects on immunological parameters4. To develop and validate an immunological…
Core StudyPrimary objective• To compare the efficacy of E5501 (in addition to standard of care) to eltrombopag (in addition to standard of care) for the treatment of adult subjects with chronic immune thrombocytopenia (idiopathic thrombocytopenic…
Part 1 (open-label, 8 week): safety and tolerability of eltrombopag, optimal dose escalation scheme for use in Part 2, PK.Part 2: Primary: the reduction in the number of clinically relevant thrombocytopenic events (*Grade 3 hemorrhagic adverse…
Several observational studies have shown that Citrus/Cydonia comp. might be an effective treatment option for patients suffering from seasonal allergic rhinitis. In these studies Citrus/Cydonia comp. was either administered subcutaneously or given…
To provide continuing treatment with eltrombopag for subjects who are currently participating in a GSK sponsored investigational study of eltrombopag (parent study) and to collect long term safety data.
The objective of this trial is to investigate whether Eltrombopag added to standard immunosuppressive treatment increases the rate of early (at three months) complete response and blood counts and can be use as front-line therapy for SAA treatment.
To compare the effect of eltrombopag and IVIG on the achievement of the platelet count threshold before and after surgery.